Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2012, Article ID 408131, 13 pages
http://dx.doi.org/10.1155/2012/408131
Review Article

Current and Emerging Therapeutic Options in Adrenocortical Cancer Treatment

1Endocrinology, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, Faculty of Medicine and Psychology, “Sapienza” University of Rome, Via di Grottarossa, 1035, 00189 Rome, Italy
2Research Center, San Pietro Hospital Fatebenefratelli, Via Cassia 600, 00189/Rome, Italy

Received 23 April 2012; Revised 26 June 2012; Accepted 27 June 2012

Academic Editor: Marialuisa Appetecchia

Copyright © 2012 Antonio Stigliano et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. National Cancer Institute, “Third national cancer survey: incidental data,” DHEW publication no. (NIH) 75–787. NCI Monogr 41, 1975.
  2. A. P. B. Dackiw, J. E. Lee, R. F. Gagel, and D. B. Evans, “Adrenal cortical carcinoma,” World Journal of Surgery, vol. 25, no. 7, pp. 914–926, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Bielinska, H. Parviainen, S. Kiiveri, M. Heikinheimo, and D. B. Wilson, “Review paper: origin and molecular pathology of adrenocortical neoplasms,” Veterinary Pathology, vol. 46, no. 2, pp. 194–210, 2009. View at Google Scholar · View at Scopus
  4. A. Patalano, V. Brancato, and F. Mantero, “Adrenocortical cancer treatment,” Hormone Research, vol. 71, no. 1, pp. 99–104, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. C. Gicquel, X. Bertagna, and Y. Le Bouc, “Recent advances in the pathogenesis of adrenocortical tumours,” European Journal of Endocrinology, vol. 133, no. 2, pp. 133–144, 1995. View at Google Scholar · View at Scopus
  6. C. Gicquel, X. Bertagna, V. Gaston et al., “Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors,” Cancer Research, vol. 61, no. 18, pp. 6762–6767, 2001. View at Google Scholar · View at Scopus
  7. H. Bläker, C. Sutter, M. Kadmon et al., “Analysis of somatic APC mutations in rare extracolonic tumors of patients with familial adenomatous polyposis coli,” Genes Chromosomes and Cancer, vol. 41, no. 2, pp. 93–98, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. F. Tissier, C. Cavard, L. Groussin et al., “Mutations of β-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors,” Cancer Research, vol. 65, no. 17, pp. 7622–7627, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Caron de Fromentel and T. Soussi, “TP53 tumor suppressor gene: a model for investigating human mutagenesis,” Genes Chromosomes and Cancer, vol. 4, no. 1, pp. 1–15, 1992. View at Google Scholar · View at Scopus
  10. M. Hisada, J. E. Garber, C. Y. Fung, J. F. Fraumeni, and F. P. Li, “Multiple primary cancers in families with Li-Fraumeni syndrome,” Journal of the National Cancer Institute, vol. 90, no. 8, pp. 606–611, 1998. View at Google Scholar · View at Scopus
  11. T. Yano, M. Linehan, P. Anglard et al., “Genetic changes in human adrenocortical carcinomas,” Journal of the National Cancer Institute, vol. 81, no. 7, pp. 518–523, 1989. View at Google Scholar · View at Scopus
  12. F. Beuschlein, M. Reincke, M. Karl et al., “Clonal composition of human adrenocortical neoplasms,” Cancer Research, vol. 54, no. 18, pp. 4927–4932, 1994. View at Google Scholar · View at Scopus
  13. M. A. Blake, J. M. A. Slattery, M. K. Kalra et al., “Adrenal lesions: characterization with fused PET/CT image in patients with proved or suspected malignancy—initial experience,” Radiology, vol. 238, no. 3, pp. 970–977, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. I. Ilias, A. Sahdev, R. H. Reznek, A. B. Grossman, and K. Pacak, “The optimal imaging of adrenal tumours: a comparison of different methods,” Endocrine-Related Cancer, vol. 14, no. 3, pp. 587–599, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Fassnacht, W. Kenn, and B. Allolio, “Adrenal tumors: how to establish malignancy?” Journal of Endocrinological Investigation, vol. 27, no. 4, pp. 387–399, 2004. View at Google Scholar · View at Scopus
  16. T. M. Seccia, A. Fassina, G. G. Nussdorfer, A. C. Pessina, and G. P. Rossi, “Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn's syndrome with an ominous clinical course,” Endocrine-Related Cancer, vol. 12, no. 1, pp. 149–159, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Fassnacht and B. Allolio, “Clinical management of adrenocortical carcinoma,” Best Practice and Research, vol. 23, no. 2, pp. 273–289, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Assié, G. Antoni, F. Tissier et al., “Prognostic parameters of metastatic adrenocortical carcinoma,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 1, pp. 148–154, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Stojadinovic, R. A. Ghossein, A. Hoos et al., “Adrenocortical carcinoma: clinical, morphologic, and molecular characterization,” Journal of Clinical Oncology, vol. 20, no. 4, pp. 941–950, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. D. A. Macfarlane, “Cancer of the adrenal cortex. The natural history, prognosis and treatment in a study of fifty-five cases,” Annals of the Royal College of Surgeons of England, vol. 23, no. 3, pp. 155–186, 1958. View at Google Scholar · View at Scopus
  21. M. Sullivan, M. Boileau, and C. V. Hodges, “Adrenal cortical carcinoma,” Journal of Urology, vol. 120, no. 6, pp. 660–665, 1978. View at Google Scholar · View at Scopus
  22. M. Fassnacht, S. Johanssen, M. Quinkler et al., “Limited prognostic value of the 2004 international union against cancer staging classification for adrenocortical carcinoma,” Cancer, vol. 115, no. 2, pp. 243–250, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. G. Lughezzani, M. Sun, P. Perrotte et al., “The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation,” European Journal of Cancer, vol. 46, no. 4, pp. 713–719, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Icard, P. Goudet, C. Charpenay et al., “Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons Study Group,” World Journal of Surgery, vol. 25, no. 7, pp. 891–897, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. M. D. Wooten and D. K. King, “Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature,” Cancer, vol. 72, no. 11, pp. 3145–3155, 1993. View at Google Scholar
  26. G. Abiven, J. Coste, L. Groussin et al., “Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 7, pp. 2650–2655, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. B. Polat, M. Fassnacht, L. Pfreundner et al., “Radiotherapy in adrenocortical carcinoma,” Cancer, vol. 115, no. 13, pp. 2816–2823, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. B. Allolio, S. Hahner, D. Weismann, and M. Fassnacht, “Management of adrenocortical carcinoma,” Clinical Endocrinology, vol. 60, no. 3, pp. 273–287, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. D. E. Schteingart, G. M. Doherty, P. G. Gauger et al., “Management of patients with adrenal cancer: recommendations of an international consensus conference,” Endocrine-Related Cancer, vol. 12, no. 3, pp. 667–680, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Berruti, M. Terzolo, P. Sperone et al., “Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial,” Endocrine-Related Cancer, vol. 12, no. 3, pp. 657–666, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. G. Abiven, J. Coste, L. Groussin et al., “Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 7, pp. 2650–2655, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. T. J. Giordano, D. G. Thomas, R. Kuick et al., “Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis,” American Journal of Pathology, vol. 162, no. 2, pp. 521–531, 2003. View at Google Scholar · View at Scopus
  33. F. Crucitti, R. Bellantone, A. Ferrante et al., “The italian registry for adrenal cortical carcinoma: analysis of a multiinstitutional series of 129 patients,” Surgery, vol. 119, no. 2, pp. 161–170, 1996. View at Publisher · View at Google Scholar · View at Scopus
  34. D. Bergenstal, M. Lipsett, R. Moy, and R. Hertz, “Regression of adrenal cancer and suppression of adrenal function in men by o, p′-DDD,” Transactions of American Physicians, vol. 72, p. 341, 1959. View at Google Scholar
  35. J. P. Luton, S. Cerdas, L. Billaud et al., “Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy,” The New England Journal of Medicine, vol. 322, no. 17, pp. 1195–1201, 1990. View at Google Scholar · View at Scopus
  36. R. M. Bukowski, M. Wolfe, H. S. Levine et al., “Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study,” Journal of Clinical Oncology, vol. 11, no. 1, pp. 161–165, 1993. View at Google Scholar · View at Scopus
  37. T. S. Khan, H. Imam, C. Juhlin et al., “Streptozocin and o,p′DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use,” Annals of Oncology, vol. 11, no. 10, pp. 1281–1287, 2000. View at Publisher · View at Google Scholar · View at Scopus
  38. D. E. Schteingart, “Conventional and novel strategies in the treatment of adrenocortical cancer,” Brazilian Journal of Medical and Biological Research, vol. 33, no. 10, pp. 1197–1200, 2000. View at Google Scholar · View at Scopus
  39. S. Hahner and M. Fassnacht, “Mitotane for adrenocortical carcinoma treatment,” Current Opinion in Investigational Drugs, vol. 6, no. 4, pp. 386–394, 2005. View at Google Scholar · View at Scopus
  40. M. Terzolo, A. Angeli, M. Fassnacht et al., “Adjuvant mitotane treatment for adrenocortical carcinoma,” The New England Journal of Medicine, vol. 356, no. 23, pp. 2372–2380, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. S. K. Williamson, D. Lew, G. J. Miller et al., “Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study,” Cancer, vol. 88, no. 5, pp. 1159–1165, 2000. View at Google Scholar
  42. R. Bonacci, A. Gigliotti, E. Baudin et al., “Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma,” British Journal of Cancer, vol. 78, no. 4, pp. 546–549, 1998. View at Google Scholar · View at Scopus
  43. M. A. Burgess, S. S. Legha, and R. V. Sellin, “Chemotherapy with cisplatinum and etoposide (UP16) for patients with advanced adrenal cortical carcinoma (ACC),” Proceedings of the Annals of Society of Clinical Oncology, vol. 12, p. 188, 1993. View at Google Scholar
  44. R. F. Pommier and M. F. Brennan, “An eleven-year experience with adrenocortical carcinoma,” Surgery, vol. 112, no. 6, pp. 963–971, 1992. View at Google Scholar · View at Scopus
  45. S. P. Hedican and F. F. Marshall, “Adrenocortical carcinoma with intracaval extension,” Journal of Urology, vol. 158, no. 6, pp. 2056–2061, 1997. View at Publisher · View at Google Scholar · View at Scopus
  46. R. D. Schulick and M. F. Brennan, “Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma,” Annals of Surgical Oncology, vol. 6, no. 8, pp. 719–726, 1999. View at Google Scholar · View at Scopus
  47. L. E. Harrison, P. B. Gaudin, and M. F. Brennan, “Pathologic features of prognostic significance for adrenocortical carcinoma after curative resection,” Archives of Surgery, vol. 134, no. 2, pp. 181–185, 1999. View at Publisher · View at Google Scholar · View at Scopus
  48. S. Gaujoux, S. Bonnet, and B. Dousset, “Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients,” European Urology, vol. 58, no. 4, pp. 609–615, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. F. Porpiglia, C. Fiori, F. Daffara et al., “Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer,” European Urology, vol. 57, no. 5, pp. 873–878, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. J. Reibetanz, C. Jurowich, I. Erdogan et al., “Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma,” Annals of Surgery, vol. 25, no. 2, pp. 363–369, 2012. View at Google Scholar
  51. A. A. Nelson and G. Woodard, “Adrenal cortical atrophy and liver damage produced in dogs by feeding,” Federation Proceedings, vol. 7, no. 1, part 1, p. 277, 1948. View at Google Scholar · View at Scopus
  52. Y. Touitou, A. Bogdan, and J. P. Luton, “Changes in corticosteroid synthesis of the human adrenal cortex in vitro, induced by treatment with o,p′-DDD for Cushing's syndrome: evidence for the sites of action of the drug,” Journal of Steroid Biochemistry, vol. 9, no. 12, pp. 1217–1224, 1978. View at Google Scholar · View at Scopus
  53. D. M. Bergenstal, R. Hertz, M. B. Lipsett, and R. H. Moy, “Chemotherapy of adrenocortical cancer with o, p′-DDD,” Annals of Internal Medicine, vol. 53, no. 4, pp. 672–682, 1960. View at Google Scholar
  54. H. van Slooten, A. J. Moolenaar, A. P. van Seters, and D. Smeenk, “The treatment of adenocortical carcinoma with o,p'-DDD: prognostic simplications of serum level monitoring,” European Journal of Cancer and Clinical Oncology, vol. 20, no. 1, pp. 47–53, 1984. View at Google Scholar · View at Scopus
  55. I. G. Hermsen, M. Fassnacht, M. Terzolo et al., “Plasma concentrations of o,p′DDD, o,p′DDA, and o,p′DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study,” Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 6, pp. 1844–1851, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. N. P. van Erp, H. J. Guchelaar, B. A. Ploeger, J. A. Romijn, J. Den Hartigh, and H. Gelderblom, “Mitotane has a strong and a durable inducing effect on CYP3A4 activity,” European Journal of Endocrinology, vol. 164, no. 4, pp. 621–626, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. L. S. Kirschner, “Emerging treatment strategies for adrenocortical carcinoma: a new hope,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 1, pp. 14–21, 2006. View at Publisher · View at Google Scholar · View at Scopus
  58. S. E. Bates, C. Y. Shieh, L. A. Mickley et al., “Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical carcinomas,” Journal of Clinical Endocrinology and Metabolism, vol. 73, no. 1, pp. 18–29, 1991. View at Google Scholar · View at Scopus
  59. H. R. Haak, J. Hermans, C. J. H. Van de Velde et al., “Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients,” British Journal of Cancer, vol. 69, no. 5, pp. 947–951, 1994. View at Google Scholar · View at Scopus
  60. J. Bertherat, J. Coste, and X. Bertagna, “Adjuvant mitotane in adrenocortical carcinoma,” The New England Journal of Medicine, vol. 357, no. 12, pp. 1256–1257, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. H. van Slooten, A. P. van Seters, D. Smeenk, and A. J. Moolenaar, “O,p′-DDD (mitotane) levels in plasma and tissues during chemotherapy and at autopsy,” Cancer Chemotherapy and Pharmacology, vol. 9, no. 2, pp. 85–88, 1982. View at Google Scholar · View at Scopus
  62. E. Baudin, G. Pellegriti, M. Bonnay et al., “Impact of monitoring plasma 1,1 dichlorodiphenildichloroethane (o,p′DDD) levels on the treatment of patients with adrenocortical carcinoma,” Cancer, vol. 92, no. 6, pp. 1385–1392, 2001. View at Google Scholar
  63. A. T. Phan, “Adrenal cortical carcinoma-review of current knowledge and treatment practices,” Hematology/Oncology Clinics of North America, vol. 21, no. 3, pp. 489–507, 2007. View at Publisher · View at Google Scholar · View at Scopus
  64. M. Wandoloski, K. J. Bussey, and M. J. Demeure, “Adrenocortical Cancer,” Surgical Clinics of North America, vol. 89, no. 5, pp. 1255–1267, 2009. View at Publisher · View at Google Scholar · View at Scopus
  65. A. Lacroix, “Approach to the patient with adrenocortical carcinoma,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 11, pp. 4812–4822, 2010. View at Publisher · View at Google Scholar · View at Scopus
  66. A. A. Kasperlik-Zaluska, B. M. Migdalska, S. Zgliczynski, and A. M. Makowska, “Adrenocortical carcinoma. A clinical study and treatment results of 52 patients,” Cancer, vol. 75, no. 10, pp. 2587–2591, 1995. View at Google Scholar
  67. B. L. Wajchenberg, M. A. Albergaria Pereira, B. B. Medonca et al., “Adrenocortical carcinoma: clinical and laboratory observations,” Cancer, vol. 88, no. 4, pp. 711–736, 2000. View at Google Scholar
  68. M. Fassnacht, M. Terzolo, B. Allolio et al., “Combination chemotherapy in advanced adrenocortical carcinoma,” The New England Journal of Medicine, vol. 366, no. 23, pp. 2189–2197, 2012. View at Google Scholar
  69. R. Libè, A. Fratticci, and J. Bertherat, “Adrenocortical cancer: pathophysiology and clinical management,” Endocrine-Related Cancer, vol. 14, no. 1, pp. 13–28, 2007. View at Publisher · View at Google Scholar · View at Scopus
  70. A. Sabolch, M. Feng, K. Griffith, G. Hammer, G. Doherty, and E. Ben-Josef, “Adjuvant and definitive radiotherapy for adrenocortical carcinoma,” International Journal of Radiation Oncology Biology Physics, vol. 80, no. 5, pp. 1477–1484, 2011. View at Publisher · View at Google Scholar · View at Scopus
  71. L. J. Tacon, R. S. Prichard, P. S. H. Soon, B. G. Robinson, R. J. Clifton-Bligh, and S. B. Sidhu, “Current and emerging therapies for advanced adrenocortical carcinoma,” Oncologist, vol. 16, no. 1, pp. 36–48, 2011. View at Publisher · View at Google Scholar · View at Scopus
  72. M. Fassnacht, S. Hahner, B. Polat et al., “Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 11, pp. 4501–4504, 2006. View at Publisher · View at Google Scholar · View at Scopus
  73. L. Zini, F. Porpiglia, and M. Fassnacht, “Contemporary management of adrenocortical carcinoma,” European Urology, vol. 60, no. 5, pp. 1055–1065, 2011. View at Publisher · View at Google Scholar · View at Scopus
  74. M. Fassnacht and B. Allolio, “What is the best approach to an apparently nonmetastatic adrenocortical carcinoma?” Clinical Endocrinology, vol. 73, no. 5, pp. 561–565, 2010. View at Publisher · View at Google Scholar · View at Scopus
  75. A. M. Markoe, W. Serber, B. Micaily, and L. W. Brady, “Radiation therapy for adjunctive treatment of adrenal cortical carcinoma,” American Journal of Clinical Oncology, vol. 14, no. 2, pp. 170–174, 1991. View at Google Scholar · View at Scopus
  76. L. Cerquetti, B. Bucci, R. Marchese et al., “Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines,” Endocrine-Related Cancer, vol. 15, no. 2, pp. 623–634, 2008. View at Publisher · View at Google Scholar · View at Scopus
  77. L. Cerquetti, C. Sampaoli, D. Amendola et al., “Mitotane sensitizes adrenocortical cancer cells to ionizing radiations by involvement of the cyclin B1/CDK complex in G2 arrest and mismatch repair enzymes modulation,” International Journal of Oncology, vol. 37, no. 2, pp. 493–501, 2010. View at Publisher · View at Google Scholar · View at Scopus
  78. I. G. C. Hermsen, Y. E. Groenen, M. W. Dercksen, J. Theuws, and H. R. Haak, “Response to radiation therapy in adrenocortical carcinoma,” Journal of Endocrinological Investigation, vol. 33, no. 10, pp. 712–714, 2010. View at Publisher · View at Google Scholar · View at Scopus
  79. D. F. Maluf, B. H. de Oliveira, and E. Lalli, “Therapy of adrenocortical cancer: present and future,” American Journal of Cancer Research, vol. 1, no. 2, pp. 222–232, 2011. View at Google Scholar
  80. A. C. Latronico, E. M. Pinto, S. Domenice et al., “An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 10, pp. 4970–4973, 2001. View at Publisher · View at Google Scholar · View at Scopus
  81. F. M. Barlaskar and G. D. Hammer, “The molecular genetics of adrenocortical carcinoma,” Reviews in Endocrine and Metabolic Disorders, vol. 8, no. 4, pp. 343–348, 2007. View at Publisher · View at Google Scholar · View at Scopus
  82. A. de Reyniès, G. Assié, D. S. Rickman et al., “Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival,” Journal of Clinical Oncology, vol. 27, no. 7, pp. 1108–1115, 2009. View at Publisher · View at Google Scholar · View at Scopus
  83. F. M. Barlaskar, A. C. Spalding, J. H. Heaton et al., “Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 1, pp. 204–212, 2009. View at Publisher · View at Google Scholar · View at Scopus
  84. B. Ragazzon, G. Assié, and J. Bertherat, “Transcriptome analysis of adrenocortical cancers: from molecular classification to the identification of new treatments,” Endocrine-Related Cancer, vol. 18, no. 2, pp. R15–R27, 2011. View at Publisher · View at Google Scholar · View at Scopus
  85. C. P. Carden, S. Frentzas, M. Langham et al., “Preliminary activity in adrenocortical tumor (ACC) in phase I dose escalation study of intermittent oral dosing of OSI-906, a small-molecule insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor in patients with advanced solid tumors,” Journal of Clinical Oncology, vol. 27, no. 15, p. 3544, 2009. View at Google Scholar
  86. P. Haluska, F. Worden, D. Olmos et al., “Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma,” Cancer Chemotherapy and Pharmacology, vol. 65, no. 4, pp. 765–773, 2010. View at Publisher · View at Google Scholar · View at Scopus
  87. T. J. Giordano, “Adrenocortical tumors an integrated clinical, pathologic, and molecular approach at the university of Michigan,” Archives of Pathology and Laboratory Medicine, vol. 134, no. 10, pp. 1440–1443, 2010. View at Google Scholar · View at Scopus
  88. M. Doghman, A. El Wakil, B. Cardinaud et al., “Regulation of IGF—mTOR signalling by miRNA in childhood adrenocortical tumors,” Cancer Research, vol. 70, no. 11, pp. 4666–4675, 2010. View at Publisher · View at Google Scholar · View at Scopus
  89. M. C. De Martino, P. M. van Koetsveld, R. Pivonello, and L. J. Hofland, “Role of the mTOR pathway in normal and tumoral adrenal cells,” Neuroendocrinology, vol. 92, no. 1, pp. 28–34, 2010. View at Publisher · View at Google Scholar · View at Scopus
  90. A. Naing, R. Kurzrock, A. Burger et al., “Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer,” Clinical Cancer Research, vol. 17, no. 18, pp. 6052–6060, 2011. View at Google Scholar
  91. S. Wortmann, M. Quinkler, C. Ritter et al., “Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma,” European Journal of Endocrinology, vol. 162, no. 2, pp. 349–356, 2010. View at Publisher · View at Google Scholar · View at Scopus
  92. R. Chacón, G. Tossen, F. S. Loria, and M. Chacón, “CASE 2. Response in a patient with metastatic adrenal cortical carcinoma with thalidomide,” Journal of Clinical Oncology, vol. 23, no. 7, pp. 1579–1580, 2005. View at Publisher · View at Google Scholar · View at Scopus
  93. M. Fassnacht, M. C. Kreissl, D. Weismann, and B. Allolio, “New targets and therapeutic approaches for endocrine malignancies,” Pharmacology and Therapeutics, vol. 123, no. 1, pp. 117–141, 2009. View at Publisher · View at Google Scholar · View at Scopus
  94. J. O. Lee, K. W. Lee, C. J. Kim et al., “Metastatic adrenocortical carcinoma treated with sunitinib: a case report,” Japanese Journal of Clinical Oncology, vol. 39, no. 3, pp. 183–185, 2009. View at Publisher · View at Google Scholar · View at Scopus
  95. D. S. Hong, S. M. Sebti, R. A. Newman et al., “Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies,” Clinical Cancer Research, vol. 15, no. 22, pp. 7061–7068, 2009. View at Publisher · View at Google Scholar · View at Scopus
  96. C. Butler, W. M. Butler, and A. A. Rizvi, “Sustained remission with the kinase inhibitor sorafenib in stage IV metastatic adrenocortical carcinoma,” Endocrine Practice, vol. 16, no. 3, pp. 441–445, 2010. View at Publisher · View at Google Scholar · View at Scopus
  97. A. Berruti, P. Sperone, A. Ferrero et al., “Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma,” European Journal of Endocrinology, vol. 166, no. 3, pp. 451–458, 2012. View at Google Scholar
  98. T. C. Gangadhar, E. E. W. Cohen, K. Wu et al., “Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies,” Clinical Cancer Research, vol. 17, no. 7, pp. 1956–1963, 2011. View at Publisher · View at Google Scholar · View at Scopus
  99. Y. Z. Xu, Y. Zhu, Z. J. Shen et al., “Significance of heparanase-1 and vascular endothelial growth factor in adrenocortical carcinoma angiogenesis: potential for therapy,” Endocrine, vol. 40, no. 3, pp. 445–451, 2011. View at Publisher · View at Google Scholar · View at Scopus
  100. G. Assié, M. Guillaud-Bataille, B. Ragazzon, X. Bertagna, J. Bertherat, and E. Clauser, “The pathophysiology, diagnosis and prognosis of adrenocortical tumors revisited by transcriptome analyses,” Trends in Endocrinology and Metabolism, vol. 21, no. 5, pp. 325–334, 2010. View at Publisher · View at Google Scholar · View at Scopus
  101. K. Dorfinger, H. Vierhapper, A. Wilfing et al., “The effects of suramin on human adrenocortical cells in vitro: suramin inhibits cortisol secretion and adrenocortical cell growth,” Metabolism, vol. 40, no. 10, pp. 1020–1024, 1991. View at Publisher · View at Google Scholar · View at Scopus
  102. W. Arlt, M. Reincke, L. Siekmann, W. Winkelmann, and B. Allolio, “Suramin in adrenocortical cancer: limited efficacy and serious toxicity,” Clinical Endocrinology, vol. 41, no. 3, pp. 299–307, 1994. View at Google Scholar · View at Scopus
  103. M. Quinkler, S. Hahner, S. Wortmann et al., “Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 6, pp. 2057–2062, 2008. View at Publisher · View at Google Scholar · View at Scopus
  104. V. Samnotra, R. Vassilopoulou-Sellin, A. T. Fojo et al., “A phase II trial of gefitinib monotherapy in patients with unresectable adrenocortical carcinoma (ACC),” Journal of Clinical Oncology, vol. 27, no. 18, p. 15527, 2007. View at Google Scholar
  105. P. Adam, S. Hahner, M. Hartmann et al., “Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcome,” Modern Pathology, vol. 23, no. 12, pp. 1596–1604, 2010. View at Publisher · View at Google Scholar · View at Scopus
  106. D. J. Gross, G. Munter, M. Bitan et al., “The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R,” Endocrine-Related Cancer, vol. 13, no. 2, pp. 535–540, 2006. View at Publisher · View at Google Scholar · View at Scopus
  107. C. L. Ronchi, S. Sbiera, L. Kraus et al., “Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy,” Endocrine-Related Cancer, vol. 16, no. 3, pp. 907–918, 2009. View at Publisher · View at Google Scholar · View at Scopus
  108. K. Takara, T. Sakaeda, and K. Okumura, “An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy,” Current Pharmaceutical Design, vol. 12, no. 3, pp. 273–286, 2006. View at Publisher · View at Google Scholar · View at Scopus
  109. H. Fridborg, R. Larsson, C. Juhlin et al., “P-glycoprotein expression and activity of resistance modifying agents in primary cultures of human renal and adrenocortical carcinoma cells,” Anticancer Research, vol. 14, no. 3 A, pp. 1009–1016, 1994. View at Google Scholar · View at Scopus
  110. N. Feller, K. Hoekman, C. M. Kuiper et al., “A patient with adrenocortical carcinoma: characterization of its biological activity and drug resistance profile,” Clinical Cancer Research, vol. 3, no. 3, pp. 389–394, 1997. View at Google Scholar · View at Scopus
  111. J. Abraham, S. Bakke, A. Rutt et al., “A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist,” Cancer, vol. 94, no. 9, pp. 2333–2343, 2002. View at Publisher · View at Google Scholar · View at Scopus
  112. M. J. Betz, I. Shapiro, M. Fassnacht, S. Hahner, M. Reincke, and F. Beuschlein, “Peroxisome proliferator-activated receptor-γ agonists suppress adrenocortical tumor cell proliferation and induce differentiation,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 7, pp. 3886–3896, 2005. View at Publisher · View at Google Scholar · View at Scopus
  113. P. Ferruzzi, E. Ceni, M. Tarocchi et al., “Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 3, pp. 1332–1339, 2005. View at Publisher · View at Google Scholar · View at Scopus
  114. G. Cantini, A. Lombardi, E. Piscitelli et al., “Rosiglitazone inhibits adrenocortical cancer cell proliferation by interfering with the IGF-IR intracellular signaling,” PPAR Research, vol. 2008, Article ID 904041, 11 pages, 2008. View at Publisher · View at Google Scholar · View at Scopus
  115. M. Luconi, M. Mangoni, S. Gelmini et al., “Rosiglitazone impairs proliferation of human adrenocortical cancer: preclinical study in a xenograft mouse model,” Endocrine-Related Cancer, vol. 17, no. 1, pp. 169–177, 2010. View at Publisher · View at Google Scholar · View at Scopus
  116. L. Cerquetti, C. Sampaoli, D. Amendola et al., “Rosiglitazone induces autophagy in H295R and cell cycle deregulation in SW13 adrenocortical cancer cells,” Experimental Cell Research, vol. 317, no. 10, pp. 1397–1410, 2011. View at Publisher · View at Google Scholar · View at Scopus
  117. A. C. Kim, F. M. Barlaskar, J. H. Heaton et al., “In search of adrenocortical stem and progenitor cells,” Endocrine Reviews, vol. 30, no. 3, pp. 241–263, 2009. View at Publisher · View at Google Scholar · View at Scopus
  118. S. Gaujoux, S. Grabar, M. Fassnacht et al., “β-catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma,” Clinical Cancer Research, vol. 17, no. 2, pp. 328–336, 2011. View at Publisher · View at Google Scholar · View at Scopus
  119. M. Doghman, J. Cazareth, and E. Lalli, “The T cell factor/β-catenin antagonist PKF115-584 inhibits proliferation of adrenocortical carcinoma cells,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 8, pp. 3222–3225, 2008. View at Publisher · View at Google Scholar · View at Scopus
  120. M. J. Demeure, K. J. Bussey, and L. S. Kirschner, “Targeted therapies for adrenocortical carcinoma: IGF and beyond,” Hormone Cancer, vol. 2, no. 6, pp. 385–392, 2011. View at Google Scholar
  121. K. Garber, “Drugging the Wnt pathway: problems and progress,” Journal of the National Cancer Institute, vol. 101, no. 8, pp. 548–550, 2009. View at Publisher · View at Google Scholar · View at Scopus
  122. M. Q. Almeida, I. C. Soares, T. C. Ribeiro et al., “Steroidogenic factor 1 overexpression and gene amplification are more frequent in adrenocortical tumors from children than from adults,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 3, pp. 1458–1462, 2010. View at Publisher · View at Google Scholar · View at Scopus
  123. S. Sbiera, S. Schmull, G. Assie et al., “High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 10, pp. E161–E171, 2010. View at Publisher · View at Google Scholar · View at Scopus
  124. M. Doghman, T. Karpova, G. A. Rodrigues et al., “Increased steroidogenic factor-1 dosage triggers adrenocortical cell proliferation and cancer,” Molecular Endocrinology, vol. 21, no. 12, pp. 2968–2987, 2007. View at Publisher · View at Google Scholar · View at Scopus
  125. A. Ehrlund, P. Jonsson, L. L. Vedin et al., “Knockdown of SF-1 and RNF31 affects components of steroidogenesis, TGFâ, and Wnt/â-catenin signaling in adrenocortical carcinoma cells,” PLoS One, vol. 7, no. 3, Article ID e32080, 2012. View at Google Scholar
  126. M. Doghman, J. Cazareth, D. Douguet, F. Madoux, P. Hodder, and E. Lalli, “Inhibition of adrenocortical carcinoma cell proliferation by steroidogenic factor-1 inverse agonists,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 6, pp. 2178–2183, 2009. View at Publisher · View at Google Scholar · View at Scopus
  127. Y. Chuman, Z. Zhan, and T. Fojo, “Construction of gene therapy vectors targeting adrenocortical cells: Enhancement of activity and specificity with agents modulating the cyclic adenosine 3′,5′-monophosphate pathway,” Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 1, pp. 253–262, 2000. View at Publisher · View at Google Scholar · View at Scopus
  128. S. Sbiera, S. Wortmann, and M. Fassnacht, “Dendritic cell based immunotherapy—a promising therapeutic approach for endocrine malignancies,” Hormone and Metabolic Research, vol. 40, no. 2, pp. 89–98, 2008. View at Publisher · View at Google Scholar · View at Scopus
  129. C. Papewalis, M. Fassnacht, H. S. Willenberg et al., “Dendritic cells as potential adjuvant for immunotherapy in adrenocortical carcinoma,” Clinical Endocrinology, vol. 65, no. 2, pp. 215–222, 2006. View at Publisher · View at Google Scholar · View at Scopus
  130. D. Ortmann, J. Hausmann, F. Beuschlein et al., “Steroidogenic acute regulatory (StaR)-directed immunotherapy protects against tumor growth of StaR-expressing Sp2-0 cells in a rodent adrenocortical carcinoma model,” Endocrinology, vol. 145, no. 4, pp. 1760–1766, 2004. View at Publisher · View at Google Scholar · View at Scopus
  131. L. Barzon, G. Masi, M. Pacenti et al., “Expression of aromatase and estrogen receptors in human adrenocortical tumors,” Virchows Archiv, vol. 452, no. 2, pp. 181–191, 2008. View at Publisher · View at Google Scholar · View at Scopus
  132. J. Matthews and J. A. Gustafsson, “Estrogen signaling: a subtle balance between ER alpha and ER beta,” Mol Interv, vol. 3, no. 5, pp. 281–292, 2003. View at Google Scholar · View at Scopus
  133. P. de Cremoux, D. Rosenberg, J. Goussard et al., “Expression of progesterone and estradiol receptors in normal adrenal cortex, adrenocortical tumors, and primary pigmented nodular adrenocortical disease,” Endocrine-Related Cancer, vol. 15, no. 2, pp. 465–474, 2008. View at Publisher · View at Google Scholar · View at Scopus
  134. D. Montanaro, M. Maggiolini, A. G. Recchia et al., “Antiestrogens upregulate estrogen receptor β expression and inhibit adrenocortical H295R cell proliferation,” Journal of Molecular Endocrinology, vol. 35, no. 2, pp. 245–256, 2005. View at Publisher · View at Google Scholar · View at Scopus
  135. R. Sirianni, F. Zolea, A. Chimento et al., “Targeting estrogen receptor á reduces adrenocortical cancer (ACC) cell growth in vitro and in vivo: potential therapeutic role of Selective Estrogen Receptor modulators (SERMs) for ACC treatment,” submitted to Journal Clinical Endocrinology and Metabolism.